Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 176 entries
Sorted by: Best Match Show Resources per page
Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis.

Immunity, inflammation and disease

Andreasen PB, Rezahosseini O, Møller DL, Wareham NE, Thomsen MT, Houmami R, Knudsen AD, Knudsen J, Kurtzhals JAL, Rostved AA, Pedersen CR, Rasmussen A, Nielsen SD.
PMID: 34713963
Immun Inflamm Dis. 2022 Jan;10(1):93-100. doi: 10.1002/iid3.546. Epub 2021 Oct 29.

BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in organ transplant recipients that may be prevented by antibiotic prophylaxis. We aimed to investigate the incidence rate (IR) of PCP and the related hospitalization and mortality rates in liver...

Cite
Andreasen PB, Rezahosseini O, Møller DL, et al. Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Immun Inflamm Dis. 2021;10(1):93-100doi: 10.1002/iid3.546.
Andreasen, P. B., Rezahosseini, O., Møller, D. L., Wareham, N. E., Thomsen, M. T., Houmami, R., Knudsen, A. D., Knudsen, J., Kurtzhals, J. A. L., Rostved, A. A., Pedersen, C. R., Rasmussen, A., & Nielsen, S. D. (2022). Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Immunity, inflammation and disease, 10(1), 93-100. https://doi.org/10.1002/iid3.546
Andreasen, Philip B, et al. "Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis." Immunity, inflammation and disease vol. 10,1 (2022): 93-100. doi: https://doi.org/10.1002/iid3.546
Andreasen PB, Rezahosseini O, Møller DL, Wareham NE, Thomsen MT, Houmami R, Knudsen AD, Knudsen J, Kurtzhals JAL, Rostved AA, Pedersen CR, Rasmussen A, Nielsen SD. Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Immun Inflamm Dis. 2022 Jan;10(1):93-100. doi: 10.1002/iid3.546. Epub 2021 Oct 29. PMID: 34713963.
Copy Download .nbib Format: NLM
Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents.

Bioorganic & medicinal chemistry letters

Fuertes M, Selas A, Trejo A, Knudsen BR, Palacios F, Alonso C.
PMID: 34952177
Bioorg Med Chem Lett. 2021 Dec 21;57:128517. doi: 10.1016/j.bmcl.2021.128517. Epub 2021 Dec 21.

This work describes the first synthesis of diethyl 6,6a,7,11b-tetrahydro-5H-indeno[2,1-c]quinolinylphosphonates 5, diethyl 7H-indeno[2,1-c]quinolinylphosphonates 6 and diethyl 7-oxo-7H-indeno[2,1-c]quinolinylphosphonates 7, which were prepared in good to high overall yields. The synthetic route involves a multicomponent reaction of 2-phosphonateaniline, aldehydes and indene as...

Cite
Fuertes M, Selas A, Trejo A, et al. Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem Lett. 2021;57:128517doi: 10.1016/j.bmcl.2021.128517.
Fuertes, M., Selas, A., Trejo, A., Knudsen, B. R., Palacios, F., & Alonso, C. (2021). Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorganic & medicinal chemistry letters, 57128517. https://doi.org/10.1016/j.bmcl.2021.128517
Fuertes, María, et al. "Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents." Bioorganic & medicinal chemistry letters vol. 57 (2021): 128517. doi: https://doi.org/10.1016/j.bmcl.2021.128517
Fuertes M, Selas A, Trejo A, Knudsen BR, Palacios F, Alonso C. Synthesis of hybrid phosphorated indenoquinolines and biological evaluation as topoisomerase I inhibitors and antiproliferative agents. Bioorg Med Chem Lett. 2021 Dec 21;57:128517. doi: 10.1016/j.bmcl.2021.128517. Epub 2021 Dec 21. PMID: 34952177.
Copy Download .nbib Format: NLM
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM.
PMID: 34645646
Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13.

PURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with PATIENTS AND METHODS: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with ≥ one prior line of...

Cite
Fountzilas C, Bajor DL, Mukherjee S, et al. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021;27(24):6726-6736doi: 10.1158/1078-0432.CCR-21-1650.
Fountzilas, C., Bajor, D. L., Mukherjee, S., Saltzman, J., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., Muhitch, J. B., Abrams, S. I., Wang, C., Hutson, A. D., Attwood, K., Hicks, K. A., Jurcevic, J. A., Kalinski, P., Iyer, R., & Boland, P. M. (2021). Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6726-6736. https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas, Christos, et al. "Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6726-6736. doi: https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021 Dec 15;27(24):6726-6736. doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. PMID: 34645646.
Copy Download .nbib Format: NLM
Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV.

Journal of acquired immune deficiency syndromes (1999)

Sørensen EW, Gelpi M, Knudsen AD, Benfield T, Mocroft A, Nielsen SD.
PMID: 34520441
J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):e36-e38. doi: 10.1097/QAI.0000000000002802.

No abstract available.

Cite
Sørensen EW, Gelpi M, Knudsen AD, et al. Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV. J Acquir Immune Defic Syndr. 2021;88(5):e36-e38doi: 10.1097/QAI.0000000000002802.
Sørensen, E. W., Gelpi, M., Knudsen, A. D., Benfield, T., Mocroft, A., & Nielsen, S. D. (2021). Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV. Journal of acquired immune deficiency syndromes (1999), 88(5), e36-e38. https://doi.org/10.1097/QAI.0000000000002802
Sørensen, Edith W, et al. "Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV." Journal of acquired immune deficiency syndromes (1999) vol. 88,5 (2021): e36-e38. doi: https://doi.org/10.1097/QAI.0000000000002802
Sørensen EW, Gelpi M, Knudsen AD, Benfield T, Mocroft A, Nielsen SD. Switch to INSTIs, but Not Long-Term Stable INSTIs, Is Associated With Excess Weight Gain in People Living With HIV. J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):e36-e38. doi: 10.1097/QAI.0000000000002802. PMID: 34520441.
Copy Download .nbib Format: NLM
TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data.

Lung cancer (Amsterdam, Netherlands)

Jakobsen AK, Yuusufi S, Madsen LB, Meldgaard P, Knudsen BR, Stougaard M.
PMID: 34974222
Lung Cancer. 2021 Dec 22;164:23-32. doi: 10.1016/j.lungcan.2021.12.010. Epub 2021 Dec 22.

OBJECTIVES: Topoisomerase 1 (TOP1) is a drug target used in anticancer treatment of various cancer types. The effect of the TOP1 drugs can be counteracted by the enzymatic activity of tyrosyl-DNA phosphodiesterase 1 (TDP1). Thus, to elucidate the relevance...

Cite
Jakobsen AK, Yuusufi S, Madsen LB, et al. TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer. 2021;164:23-32doi: 10.1016/j.lungcan.2021.12.010.
Jakobsen, A. K., Yuusufi, S., Madsen, L. B., Meldgaard, P., Knudsen, B. R., & Stougaard, M. (2021). TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung cancer (Amsterdam, Netherlands), 16423-32. https://doi.org/10.1016/j.lungcan.2021.12.010
Jakobsen, Ann-Katrine, et al. "TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data." Lung cancer (Amsterdam, Netherlands) vol. 164 (2021): 23-32. doi: https://doi.org/10.1016/j.lungcan.2021.12.010
Jakobsen AK, Yuusufi S, Madsen LB, Meldgaard P, Knudsen BR, Stougaard M. TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer. 2021 Dec 22;164:23-32. doi: 10.1016/j.lungcan.2021.12.010. Epub 2021 Dec 22. PMID: 34974222.
Copy Download .nbib Format: NLM
Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum.

Molecular biology international

Roy A, D'Annessa I, Nielsen CJ, Tordrup D, Laursen RR, Knudsen BR, Desideri A, Andersen FF.
PMID: 22091414
Mol Biol Int. 2011;2011:854626. doi: 10.4061/2011/854626. Epub 2011 May 04.

Control of diseases inflicted by protozoan parasites such as Leishmania, Trypanosoma, and Plasmodium, which pose a serious threat to human health worldwide, depends on a rather small number of antiparasite drugs, of which many are toxic and/or inefficient. Moreover,...

Cite
Roy A, D'Annessa I, Nielsen CJ, et al. Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum. Mol Biol Int. 2011;2011:854626doi: 10.4061/2011/854626.
Roy, A., D'Annessa, I., Nielsen, C. J., Tordrup, D., Laursen, R. R., Knudsen, B. R., Desideri, A., & Andersen, F. F. (2011). Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum. Molecular biology international, 2011854626. https://doi.org/10.4061/2011/854626
Roy, Amit, et al. "Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum." Molecular biology international vol. 2011 (2011): 854626. doi: https://doi.org/10.4061/2011/854626
Roy A, D'Annessa I, Nielsen CJ, Tordrup D, Laursen RR, Knudsen BR, Desideri A, Andersen FF. Peptide Inhibition of Topoisomerase IB from Plasmodium falciparum. Mol Biol Int. 2011;2011:854626. doi: 10.4061/2011/854626. Epub 2011 May 04. PMID: 22091414; PMCID: PMC3200115.
Copy Download .nbib Format: NLM
Corrigendum: Functional vagotopy in the cervical vagus nerve of the domestic pig: implications for the study of vagus nerve stimulation (2020.

Journal of neural engineering

Settell ML, Pelot NA, Knudsen BE, Dingle AM, McConico AL, Nicolai EN, Trevathan JK, Ezzell JA, Ross EK, Gustafson KJ, Shoffstall AJ, Williams JC, Zeng W, Poore SO, Populin LC, Suminski AJ, Grill WM, Ludwig KA.
PMID: 34096889
J Neural Eng. 2021 Jun 01;18(4). doi: 10.1088/1741-2552/ac01ff.

No abstract available.

Cite
Settell ML, Pelot NA, Knudsen BE, et al. Corrigendum: Functional vagotopy in the cervical vagus nerve of the domestic pig: implications for the study of vagus nerve stimulation (2020. J Neural Eng. 2021;18(4)doi: 10.1088/1741-2552/ac01ff.
Settell, M. L., Pelot, N. A., Knudsen, B. E., Dingle, A. M., McConico, A. L., Nicolai, E. N., Trevathan, J. K., Ezzell, J. A., Ross, E. K., Gustafson, K. J., Shoffstall, A. J., Williams, J. C., Zeng, W., Poore, S. O., Populin, L. C., Suminski, A. J., Grill, W. M., & Ludwig, K. A. (2021). Corrigendum: Functional vagotopy in the cervical vagus nerve of the domestic pig: implications for the study of vagus nerve stimulation (2020. Journal of neural engineering, 18(4), . https://doi.org/10.1088/1741-2552/ac01ff
Settell, Megan L, et al. "Corrigendum: Functional vagotopy in the cervical vagus nerve of the domestic pig: implications for the study of vagus nerve stimulation (2020." Journal of neural engineering vol. 18,4 (2021). doi: https://doi.org/10.1088/1741-2552/ac01ff
Settell ML, Pelot NA, Knudsen BE, Dingle AM, McConico AL, Nicolai EN, Trevathan JK, Ezzell JA, Ross EK, Gustafson KJ, Shoffstall AJ, Williams JC, Zeng W, Poore SO, Populin LC, Suminski AJ, Grill WM, Ludwig KA. Corrigendum: Functional vagotopy in the cervical vagus nerve of the domestic pig: implications for the study of vagus nerve stimulation (2020. J Neural Eng. 2021 Jun 01;18(4). doi: 10.1088/1741-2552/ac01ff. PMID: 34096889.
Copy Download .nbib Format: NLM
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM.
PMID: 34645646
Clin Cancer Res. 2021 Oct 13; doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13.

PURPOSE: We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with PATIENTS AND METHODS: In this phase Ib/II study, cetuximab was combined with pembrolizumab in patients with RASwt mCRC with ≥ one prior line of...

Cite
Fountzilas C, Bajor DL, Mukherjee S, et al. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-1650.
Fountzilas, C., Bajor, D. L., Mukherjee, S., Saltzman, J., Witkiewicz, A. K., Maguire, O., Minderman, H., Nambiar, R., Rosenheck, H. R., Knudsen, E. S., Muhitch, J. B., Abrams, S. I., Wang, C., Hutson, A. D., Attwood, K., Hicks, K. A., Jurcevic, J. A., Kalinski, P., Iyer, R., & Boland, P. M. (2021). Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas, Christos, et al. "Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-1650
Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021 Oct 13; doi: 10.1158/1078-0432.CCR-21-1650. Epub 2021 Oct 13. PMID: 34645646.
Copy Download .nbib Format: NLM
Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis.

JHEP reports : innovation in hepatology

Torp N, Israelsen M, Madsen B, Lutz P, Jansen C, Strassburg C, Mortensen C, Knudsen AW, Sorensen GL, Holmskov U, Schlosser A, Thiele M, Trebicka J, Krag A.
PMID: 34041469
JHEP Rep. 2021 Mar 29;3(3):100287. doi: 10.1016/j.jhepr.2021.100287. eCollection 2021 Jun.

BACKGROUND & AIMS: Prognostic models of cirrhosis underestimate disease severity for patients with cirrhosis and ascites. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein linked to hepatic neoangiogenesis and fibrogenesis. We investigated ascites MFAP4 as a predictor of...

Cite
Torp N, Israelsen M, Madsen B, et al. Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Rep. 2021;3(3):100287doi: 10.1016/j.jhepr.2021.100287.
Torp, N., Israelsen, M., Madsen, B., Lutz, P., Jansen, C., Strassburg, C., Mortensen, C., Knudsen, A. W., Sorensen, G. L., Holmskov, U., Schlosser, A., Thiele, M., Trebicka, J., & Krag, A. (2021). Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP reports : innovation in hepatology, 3(3), 100287. https://doi.org/10.1016/j.jhepr.2021.100287
Torp, Nikolaj, et al. "Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis." JHEP reports : innovation in hepatology vol. 3,3 (2021): 100287. doi: https://doi.org/10.1016/j.jhepr.2021.100287
Torp N, Israelsen M, Madsen B, Lutz P, Jansen C, Strassburg C, Mortensen C, Knudsen AW, Sorensen GL, Holmskov U, Schlosser A, Thiele M, Trebicka J, Krag A. Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Rep. 2021 Mar 29;3(3):100287. doi: 10.1016/j.jhepr.2021.100287. eCollection 2021 Jun. PMID: 34041469; PMCID: PMC8141937.
Copy Download .nbib Format: NLM
The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome.

Aging

Gelpi M, Mikaeloff F, Knudsen AD, Benfeitas R, Krishnan S, Svenssson Akusjärvi S, Høgh J, Murray DD, Ullum H, Neogi U, Nielsen SD.
PMID: 34635603
Aging (Albany NY). 2021 Oct 11;13(19):22732-22751. doi: 10.18632/aging.203622. Epub 2021 Oct 11.

Metabolic syndrome (MetS) is a significant factor for cardiometabolic comorbidities in people living with HIV (PLWH) and a barrier to healthy aging. The long-term consequences of HIV-infection and combination antiretroviral therapy (cART) in metabolic reprogramming are unknown. In this...

Cite
Gelpi M, Mikaeloff F, Knudsen AD, et al. The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome. Aging (Albany NY). 2021;13(19):22732-22751doi: 10.18632/aging.203622.
Gelpi, M., Mikaeloff, F., Knudsen, A. D., Benfeitas, R., Krishnan, S., Svenssson Akusjärvi, S., Høgh, J., Murray, D. D., Ullum, H., Neogi, U., & Nielsen, S. D. (2021). The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome. Aging, 13(19), 22732-22751. https://doi.org/10.18632/aging.203622
Gelpi, Marco, et al. "The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome." Aging vol. 13,19 (2021): 22732-22751. doi: https://doi.org/10.18632/aging.203622
Gelpi M, Mikaeloff F, Knudsen AD, Benfeitas R, Krishnan S, Svenssson Akusjärvi S, Høgh J, Murray DD, Ullum H, Neogi U, Nielsen SD. The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome. Aging (Albany NY). 2021 Oct 11;13(19):22732-22751. doi: 10.18632/aging.203622. Epub 2021 Oct 11. PMID: 34635603; PMCID: PMC8544298.
Copy Download .nbib Format: NLM
Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis.

Immunity, inflammation and disease

Andreasen PB, Rezahosseini O, Møller DL, Wareham NE, Thomsen MT, Houmami R, Knudsen AD, Knudsen J, Kurtzhals JAL, Rostved AA, Pedersen CR, Rasmussen A, Nielsen SD.
PMID: 34713963
Immun Inflamm Dis. 2021 Oct 29; doi: 10.1002/iid3.546. Epub 2021 Oct 29.

BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in organ transplant recipients that may be prevented by antibiotic prophylaxis. We aimed to investigate the incidence rate (IR) of PCP and the related hospitalization and mortality rates in liver...

Cite
Andreasen PB, Rezahosseini O, Møller DL, et al. Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Immun Inflamm Dis. 2021;doi: 10.1002/iid3.546.
Andreasen, P. B., Rezahosseini, O., Møller, D. L., Wareham, N. E., Thomsen, M. T., Houmami, R., Knudsen, A. D., Knudsen, J., Kurtzhals, J. A. L., Rostved, A. A., Pedersen, C. R., Rasmussen, A., & Nielsen, S. D. (2021). Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Immunity, inflammation and disease, . https://doi.org/10.1002/iid3.546
Andreasen, Philip B, et al. "Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis." Immunity, inflammation and disease vol. (2021). doi: https://doi.org/10.1002/iid3.546
Andreasen PB, Rezahosseini O, Møller DL, Wareham NE, Thomsen MT, Houmami R, Knudsen AD, Knudsen J, Kurtzhals JAL, Rostved AA, Pedersen CR, Rasmussen A, Nielsen SD. Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Immun Inflamm Dis. 2021 Oct 29; doi: 10.1002/iid3.546. Epub 2021 Oct 29. PMID: 34713963.
Copy Download .nbib Format: NLM
Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly.

Clinica chimica acta; international journal of clinical chemistry

Abildgaard A, Knudsen CS, Hoejskov CS, Greibe E, Parkner T.
PMID: 34942168
Clin Chim Acta. 2021 Dec 21;525:62-68. doi: 10.1016/j.cca.2021.12.015. Epub 2021 Dec 21.

BACKGROUND: Plasma/serum vitamin B12 (B12) is often used to screen for B12 deficiency complemented with analysis of methylmalonic acid (MMA) in case of low B12. The concentration of both analytes likely depends on age, and we, therefore, aimed at...

Cite
Abildgaard A, Knudsen CS, Hoejskov CS, et al. Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly. Clin Chim Acta. 2021;525:62-68doi: 10.1016/j.cca.2021.12.015.
Abildgaard, A., Knudsen, C. S., Hoejskov, C. S., Greibe, E., & Parkner, T. (2021). Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly. Clinica chimica acta; international journal of clinical chemistry, 52562-68. https://doi.org/10.1016/j.cca.2021.12.015
Abildgaard, Anders, et al. "Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly." Clinica chimica acta; international journal of clinical chemistry vol. 525 (2021): 62-68. doi: https://doi.org/10.1016/j.cca.2021.12.015
Abildgaard A, Knudsen CS, Hoejskov CS, Greibe E, Parkner T. Reference intervals for plasma vitamin B12 and plasma/serum methylmalonic acid in Danish children, adults and elderly. Clin Chim Acta. 2021 Dec 21;525:62-68. doi: 10.1016/j.cca.2021.12.015. Epub 2021 Dec 21. PMID: 34942168.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 176 entries